Skip to content
value.today

GeneDx Holdings Corp.

WGS
$2.1 Bmarket cap on Oct 30, 2026
1M
-6.9%
#6,116 in the world#1,592 in 🇺🇸 USA
Compare
World rank
#6,116
Revenue
$428 M
For year ending December-2025
Net income
$-21 M
-4.9% margin
SEC filing
Employees
—

GeneDx Holdings Corp. in brief

GeneDx Holdings Corp. is a listed company, based in Stamford, Connecticut, USA. Its market value was $2.1 B on 30 October 2026, which makes it the 6,116th largest listed company in the world and the 1,592nd largest in the USA on this site. In the year to December 2025 it had sales of $428 M and a net loss of $21 M. Katherine Stueland is its chief executive. Its largest product and service lines by sales in 2025 were Diagnostic Test (97%), Patients with third-party insurance (81%) and Institutional customers (16%). Its shares trade under the symbol WGS (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About GeneDx Holdings Corp.

At GeneDx, our mission is to empower everyone to live their healthiest life through genomics. GeneDx combines clinical expertise, advanced technology, and the proprietary GeneDx Infinity™ dataset to power the ExomeDx™ and GenomeDx™ tests – ranked #1 by expert geneticists and granted FDA Breakthrough Device Designation – enabling clinicians to deliver precise, fast, and actionable diagnoses. GeneDx InfinityTM also fuels discovery for biopharma while supporting the network that we believe will drive the future of precision genetic medicine. We believe that what is best for patients must be embedded in every aspect of our work, and in support of these beliefs, we value equitability, simplicity, and transparency.

From the company's annual report filed with the US SEC: read the report

GeneDx Holdings Corp. timeline

5 events, 2020–2025
  1. 2020
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 🔔
    Initial public offering as CM Life Sciences, Inc.
    Final prospectus filed with the SEC on 3 September 2020; shares registered for exchange trading on 31 August 2020.
  4. 2021
  5. ✎
    Renamed Sema4 Holdings Corp.
    Formerly CM Life Sciences, Inc..
  6. 2023
  7. ✎
    Renamed GeneDx Holdings Corp.
    Formerly Sema4 Holdings Corp..
  8. 2025
  9. 💰
    Record revenue of $428 million
    FY2025, the highest of the 7 years on record.

Events of GeneDx Holdings Corp. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$617 M$1.2 B$1.9 B$2.5 B

World rank over time

▼ down 209 places since 2026
2026-10-06: #5922#5,92220262026-10-30: #6131#6,1312026

Rank in USA: #1,555 (Oct 2026) · #1,593 (Oct 2026)

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
n/m (loss)
Price / sales (TTM)
4.6×
Price / book
6.9×
Free cash flow yield
0.7%
Net margin (TTM)
-24.1%
Operating margin
-3.1%
Return on equity
-36.0%
Liabilities / assets
41.2%
Net debt
$-50M
Revenue growth
+40.0%
R&D / revenue
16.8%

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2019: revenue $196M, net income $-30M$196MFY19Fiscal year ending Dec 2020: revenue $179M, net income $-241M$179MFY20Fiscal year ending Dec 2021: revenue $212M, net income $-245M$212MFY21Fiscal year ending Dec 2022: revenue $235M, net income $-549M$235MFY22Fiscal year ending Dec 2023: revenue $203M, net income $-176M$203MFY23Fiscal year ending Dec 2024: revenue $305M, net income $-52M$305MFY24Fiscal year ending Dec 2025: revenue $428M, net income $-21M$428MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$428M+40.0%$-13M$-21M-4.9%
Dec 2024$305M+50.8%$-23M$-52M-17.1%
Dec 2023$203M-13.7%$-181M$-176M-86.8%
Dec 2022$235M+10.6%$-668M$-549M-233.9%
Dec 2021$212M+18.3%$-446M$-245M-115.6%
Dec 2020$179M-8.6%$-242M$-241M-134.6%
Dec 2019$196M—$-30M$-30M-15.1%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$33M$19M$14M$-0.73—
Dec 2024$-29M$5M$-34M$-1.94—
Dec 2023$-180M$5M$-185M$-7.23—
Dec 2022$-319M$7M$-326M$-53.63—
Dec 2021$-190M$9M$-200M$-2.27—
Dec 2020$-93M$24M$-117M$-47036.00—
Dec 2019$-19M$12M$-31M——

Quarterly results

USD · three months to · source: SEC filings
Revenue, trailing 12 months
$461M
Net income, trailing 12 months
$-111M
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue $96M, net income $5M$96MDec ’24Three months to Mar 2025: revenue $87M, net income $-7M$87MMar ’25Three months to Jun 2025: revenue $103M, net income $11M$103MJun ’25Three months to Sep 2025: revenue $117M, net income $-8M$117MSep ’25Three months to Dec 2025 (from the annual report): revenue $121M, net income $-18M$121MDec ’25Three months to Mar 2026: revenue $102M, net income $-63M$102MMar ’26Three months to Jun 2026: revenue $114M, net income $-18M$114MJun ’26Three months to Sep 2026: revenue $123M, net income $-12M$123MSep ’26

Latest quarter to Sep 2026: revenue $123M (+5.4% on a year earlier), net income $-12M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of GeneDx Holdings Corp. with the US Securities and Exchange Commission.

Annual results

Revenue
$428 M
Operating income
$-13 M
Net income
$-21 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$524 M
Total liabilities
$216 M
Total equity
$308 M

As of December-2025

Top 100 institutional investors in GeneDx Holdings Corp.#

As of Sep 30, 2026
219 institutions held 33.7 M shares (more than all shares outstanding: lent and sub-advised shares are reported by more than one filer) on Sep 30, 2026. The ten largest hold 67.2%. Source: SEC Form 13F filings, filed through Nov 18, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in GeneDx Holdings Corp.
#InstitutionShares heldChange (shares)% heldValueFiled
1Corvex Management LP4,784,5700 (0.00%)15.96%$346 MNov 16, 2026
2Casdin Capital, LLC3,707,1640 (0.00%)12.37%$268 MNov 16, 2026
3Goldman Sachs Group Inc2,102,780+433,339 (+25.96%)7.02%$152 MNov 16, 2026
4ARK Investment Management LLC1,913,123+302,934 (+18.81%)6.38%$138 MNov 13, 2026
5BlackRock, Inc.1,693,931-12,308 (-0.72%)5.65%$122 MNov 13, 2026
6William Blair Investment Management, LLC1,560,247+159,594 (+11.39%)5.21%$113 MNov 6, 2026
7Deep Track Capital, LP1,200,000+500,000 (+71.43%)4.00%$87 MNov 16, 2026
8Millennium Management LLC1,089,123+933,548 (+600.06%)3.63%$79 MNov 16, 2026
9Wellington Management Group LLP1,087,679+739,752 (+212.62%)3.63%$79 MNov 16, 2026
10Morgan Stanley1,014,935+26,638 (+2.70%)3.39%$73 MNov 13, 2026
11Vanguard Capital Management LLC948,762+69,759 (+7.94%)3.17%$69 MNov 13, 2026
12First Light Asset Management, LLC786,901+2,978 (+0.38%)2.63%$57 MNov 16, 2026
13D. E. Shaw & Co., Inc.673,610+634,733 (+1632.67%)2.25%$49 MNov 16, 2026
14Citadel Advisors LLC668,709-196,753 (-22.73%)2.23%$48 MNov 16, 2026
15Sumitomo Mitsui Trust Group, Inc.661,809-4,772 (-0.72%)2.21%$48 MOct 29, 2026
16Amova Asset Management Americas, Inc.661,809-4,772 (-0.72%)2.21%$48 MNov 13, 2026
17Assenagon Asset Management S.A.632,413+25,547 (+4.21%)2.11%$46 MOct 15, 2026
18Geode Capital Management, LLC559,878+7,753 (+1.40%)1.87%$40 MNov 6, 2026
19State Street Corp530,215+2,400 (+0.45%)1.77%$38 MNov 12, 2026
20Gagnon Securities LLC516,284-8,581 (-1.63%)1.72%$37 MNov 5, 2026
21Zweig-DiMenna Associates LLC358,100-213,850 (-37.39%)1.19%$26 MNov 6, 2026
22Science & Technology Partners, L.P.335,435+229,048 (+215.30%)1.12%$24 MNov 16, 2026
23Aberdeen Group plc322,405-134,796 (-29.48%)1.08%$23 MNov 10, 2026
24Bank Of America Corp /de/307,809-38,402 (-11.09%)1.03%$22 MNov 16, 2026
25Dimensional Fund Advisors LP287,165+6,546 (+2.33%)0.96%$21 MNov 4, 2026
Show all 100: investors 26 to 100
Institutional investors 26 to 100 in GeneDx Holdings Corp.
#InstitutionShares heldChange (shares)% heldValueFiled
26Eventide Asset Management, LLC269,485-57 (-0.02%)0.90%$19 MNov 13, 2026
27Thrivent Financial for Lutherans227,628+125,636 (+123.18%)0.76%$16 MNov 5, 2026
28Portolan Capital Management, LLC199,770-545 (-0.27%)0.67%$14 MNov 16, 2026
29Charles Schwab Investment Management Inc197,770+19,833 (+11.15%)0.66%$14 MNov 16, 2026
30Vanguard Portfolio Management LLC194,169-3,409 (-1.73%)0.65%$14 MNov 13, 2026
31Northern Trust Corp184,016+175 (+0.10%)0.61%$13 MNov 16, 2026
32Franklin Templeton Inc183,061-97,877 (-34.84%)0.61%$13 MNov 12, 2026
33Jpmorgan Chase & Co168,587+114,200 (+209.98%)0.56%$12 MNov 12, 2026
34Alamea Verwaltungs GmbH167,041-18,948 (-10.19%)0.56%$12 MNov 16, 2026
35Gagnon Advisors, LLC163,024-14,846 (-8.35%)0.54%$12 MNov 6, 2026
36Vanguard Fiduciary Trust Co159,745+6,880 (+4.50%)0.53%$12 MNov 13, 2026
37LMR Partners LLP146,822New0.49%$11 MNov 16, 2026
38Fred Alger Management, LLC135,828+27,301 (+25.16%)0.45%$10 MNov 16, 2026
39Ashford Capital Management Inc125,684-76,302 (-37.78%)0.42%$9 MNov 16, 2026
40FMR LLC121,242+114,110 (+1599.97%)0.40%$9 MNov 10, 2026
41BNP Paribas Financial Markets118,901-4,789 (-3.87%)0.40%$9 MNov 12, 2026
42Legal Advantage Investments, Inc.98,845+31,800 (+47.43%)0.33%$7 MOct 13, 2026
43UBS Group AG97,926-110,737 (-53.07%)0.33%$7 MNov 10, 2026
44Rockefeller Capital Management L.P.97,743-53,421 (-35.34%)0.33%$7 MNov 13, 2026
45Tudor Investment Corp Et Al85,829-23,010 (-21.14%)0.29%$6 MNov 16, 2026
46IQ EQ FUND MANAGEMENT (IRELAND) Ltd79,971+13,755 (+20.77%)0.27%$6 MNov 13, 2026
47Blackstone Inc.79,918New0.27%$6 MNov 16, 2026
48BNP PARIBAS ASSET MANAGEMENT Holding S.A.77,229-76 (-0.10%)0.26%$6 MNov 13, 2026
49Trexquant Investment LP64,804New0.22%$5 MNov 16, 2026
50EFG International AG62,001+17,049 (+37.93%)0.21%$4 MNov 16, 2026
51Bank of New York Mellon Corp60,862-1,166 (-1.88%)0.20%$4 MNov 5, 2026
52Jump Financial, LLC57,174New0.19%$4 MNov 13, 2026
53Quantinno Capital Management LP54,849+1,395 (+2.61%)0.18%$4 MNov 13, 2026
54MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.54,627+17,688 (+47.88%)0.18%$4 MNov 16, 2026
55Nuveen, LLC53,818+7,660 (+16.60%)0.18%$4 MNov 10, 2026
56Nia Impact Advisors, LLC47,238+507 (+1.08%)0.16%$3 MNov 4, 2026
57Corient Private Wealth LP44,293-365 (-0.82%)0.15%$3 MNov 16, 2026
58Russell Investments Group, Ltd.44,167+32,286 (+271.74%)0.15%$3 MNov 6, 2026
59Kovack Advisors, Inc.42,917-175 (-0.41%)0.14%$3 MNov 13, 2026
60UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC39,662-14,674 (-27.01%)0.13%$3 MNov 16, 2026
61Royce & Associates LP39,640-72,496 (-64.65%)0.13%$3 MNov 9, 2026
62Envestnet Asset Management Inc39,390-3,651 (-8.48%)0.13%$3 MNov 16, 2026
63AQR Capital Management LLC39,308+10,136 (+34.75%)0.13%$3 MNov 16, 2026
64Lazard Asset Management LLC38,844+5,992 (+18.24%)0.13%$3 MNov 16, 2026
65RBF Capital, LLC37,3400 (0.00%)0.12%$3 MNov 13, 2026
66Moody Aldrich Partners LLC36,064+20,511 (+131.88%)0.12%$3 MOct 27, 2026
67Swiss National Bank36,000-4,000 (-10.00%)0.12%$3 MNov 12, 2026
68Connor, Clark & Lunn Investment Management Ltd.35,141New0.12%$3 MNov 10, 2026
69Slow Capital, Inc.34,527-7,973 (-18.76%)0.12%$2 MOct 23, 2026
70Citigroup Inc33,840-20,054 (-37.21%)0.11%$2 MNov 4, 2026
71XTX Topco Ltd33,709New0.11%$2 MNov 16, 2026
72Susquehanna International Group, LLP30,799-111,516 (-78.36%)0.10%$2 MNov 16, 2026
73First Trust Advisors LP30,312New0.10%$2 MNov 12, 2026
74Vestmark Advisory Solutions, Inc.30,098-1,993 (-6.21%)0.10%$2 MNov 16, 2026
75Stempoint Capital LP29,275New0.10%$2 MNov 16, 2026
76Price T Rowe Associates Inc /MD/28,988+97 (+0.34%)0.10%$2 MNov 16, 2026
77SRS Investment Management, LLC25,752New0.09%$2 MNov 16, 2026
78Rhumbline Advisers25,222+39 (+0.15%)0.08%$2 MNov 10, 2026
79Virtu Financial LLC24,156New0.08%$2 MNov 17, 2026
80Wells Fargo & Company/mn23,461-5,677 (-19.48%)0.08%$2 MNov 16, 2026
81California State Teachers Retirement System21,9350 (0.00%)0.07%$2 MNov 13, 2026
82Deutsche Bank AG\20,293-1,587 (-7.25%)0.07%$1 MNov 6, 2026
83Invesco Ltd.20,215+219 (+1.10%)0.07%$1 MNov 12, 2026
84Alliancebernstein L.P.20,0500 (0.00%)0.07%$1 MNov 16, 2026
85Squarepoint Ops LLC18,621New0.06%$1 MNov 9, 2026
86WINTON GROUP Ltd18,504New0.06%$1 MNov 12, 2026
87IMC-Chicago, LLC17,927+5,133 (+40.12%)0.06%$1 MNov 5, 2026
88Fox Run Management, L.L.C.17,526+10,260 (+141.21%)0.06%$1 MNov 12, 2026
89Legal & General Group Plc17,354-438 (-2.46%)0.06%$1 MNov 16, 2026
90FORA Capital, LLC16,393-16,832 (-50.66%)0.05%$1 MNov 13, 2026
91ExodusPoint Capital Management, LP16,252-8,922 (-35.44%)0.05%$1 MNov 16, 2026
92Quadrature Capital Ltd15,209-5,213 (-25.53%)0.05%$1 MNov 13, 2026
93Walleye Capital LLC15,005-52,895 (-77.90%)0.05%$1 MNov 13, 2026
94Meridiem Capital Partners LP14,099-32,665 (-69.85%)0.05%$1 MNov 16, 2026
95Dark Forest Capital Management LP14,051+570 (+4.23%)0.05%$1 MNov 16, 2026
96Manufacturers Life Insurance Company, The13,306+1,518 (+12.88%)0.04%$1 MNov 13, 2026
97VANGUARD ASSET MANAGEMENT, Ltd13,214-80 (-0.60%)0.04%$1 MNov 13, 2026
98Algert Global LLC12,932-9,000 (-41.04%)0.04%$1 MNov 17, 2026
99Osaic Holdings, Inc.12,255+4,927 (+67.24%)0.04%$1 MNov 12, 2026
100MetLife Investment Management, LLC11,5380 (0.00%)0.04%$1 MNov 16, 2026

All 219 institutional investors, with who bought and sold →

Mutual funds holding GeneDx Holdings Corp.#

180 funds in 2 countries hold shares worth $458 M (about 23.3% of the company). Since their previous reports 117 added shares and 107 sold, selling $173 M net. By country: USA 179 ($457 M), Sweden 1 ($0 M).
Mutual funds holding GeneDx Holdings Corp.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 ARK Innovation ETFARK Investment Management LLC876,607$57 M2.9%1.0%+5.5%Jul 31, 2026
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.607,773$42 M2.0%<0.01%+1.4%Jun 30, 2026
🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors523,338$36 M1.7%0.04%+12%Jun 30, 2026
🇺🇸 ARK Genomic Revolution ETFARK Investment Management LLC446,965$29 M1.5%1.9%+11%Jul 31, 2026
🇺🇸 Eventide Gilead FundEventide Asset Management, LLC266,042$18 M0.89%0.53%+56%Jun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.249,890$17 M0.83%0.02%+4.4%Jun 30, 2026
🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC218,876$14 M0.73%0.04%+16%Jul 31, 2026
🇺🇸 Franklin Small Cap Growth FundFranklin Advisers, Inc.201,666$13 M0.67%0.53%no changeJul 31, 2026
🇺🇸 iShares Russell 2000 Growth ETFBlackRock Fund Advisors184,614$13 M0.62%0.08%+19%Jun 30, 2026
🇺🇸 abrdn Healthcare Opportunities Fundabrdn Inc.171,640$12 M0.57%1.4%+85%Jun 30, 2026
🇺🇸 Strategic Advisers U.S. Total Stock FundStrategic Advisers LLC222,516$12 M0.74%0.01%+123%May 31, 2026
🇺🇸 abrdn Healthcare Investorsabrdn Inc.163,598$11 M0.55%0.82%+122%Jun 30, 2026
🇺🇸 William Blair Small-Mid Cap Growth FundWilliam Blair Investment Management, LLC126,588$9 M0.42%0.66%+73%Jun 30, 2026
🇺🇸 William Blair Small Cap Growth FundWilliam Blair Investment Management, LLC125,324$9 M0.42%0.70%+103%Jun 30, 2026
🇺🇸 Alger Small Cap Focus FundFred Alger Management, LLC130,474$8 M0.44%1.00%+8.2%Jul 31, 2026
🇺🇸 Thrivent Small-Mid Cap Equity ETFThrivent Asset Management LLC101,992$7 M0.34%0.67%+13%Jun 30, 2026
🇺🇸 Dimensional U.S. Small Cap ETFDimensional Fund Advisors LP97,509$6 M0.33%0.04%+24%Jul 31, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC110,973$6 M0.37%0.01%−0.8%May 31, 2026
🇺🇸 Schwab U.S. Small-Cap ETFCharles Schwab Investment Management, Inc.103,149$5 M0.34%0.02%−1.0%May 31, 2026
🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc.97,760$5 M0.33%0.03%+3.8%May 31, 2026
🇺🇸 ARK Venture FundARK Investment Management LLC76,976$5 M0.26%0.42%+25%Jul 31, 2026
🇺🇸 abrdn World Healthcare Fundabrdn Inc.71,515$5 M0.24%0.87%+98%Jun 30, 2026
🇺🇸 Royce Micro-Cap Trust, Inc.Royce & Associates, LP70,970$5 M0.24%0.54%+125%Jun 30, 2026
🇺🇸 U.S. Micro Cap PortfolioDimensional Fund Advisors LP71,590$5 M0.24%0.06%+4.1%Jul 31, 2026
🇺🇸 abrdn Life Sciences Investorsabrdn Inc.67,565$5 M0.23%0.67%+145%Jun 30, 2026
🇺🇸 Principal U.S. Small-Cap ETFPrincipal Global Investors, LLC66,880$5 M0.22%0.20%+7.6%Jun 30, 2026
🇺🇸 Calamos Timpani Small Cap Growth FundCalamos Advisors LLC56,759$4 M0.19%0.48%+127%Jul 31, 2026
🇺🇸 Timothy Plan Small/Mid Cap Growth FundTimothy Partners, Ltd.53,556$4 M0.18%2.1%+94%Jun 30, 2026
🇺🇸 The Hartford Small Company FundHartford Funds Management Company, LLC56,384$4 M0.19%0.54%−1.6%Jul 31, 2026
🇺🇸 Vanguard Health Care Index FundThe Vanguard Group, Inc.60,640$3 M0.20%0.02%+0.2%May 31, 2026
🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc.48,408$3 M0.16%0.04%+16%Jul 31, 2026
🇺🇸 Small Cap Growth Stock PortfolioMason Street Advisors, LLC42,072$3 M0.14%0.32%+9.1%Jun 30, 2026
🇺🇸 State Street SPDR S&P Health Care Services ETFSSGA Funds Management, Inc.41,617$3 M0.14%2.0%—Jun 30, 2026
🇺🇸 iShares U.S. Healthcare Providers ETFBlackRock Fund Advisors39,630$3 M0.13%0.23%+58%Jun 30, 2026
🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC37,388$3 M0.12%0.04%+19%Jun 30, 2026
🇺🇸 Hartford Small Company HLS FundHartford Funds Management Company, LLC36,611$3 M0.12%0.53%no changeJun 30, 2026
🇺🇸 Royce Micro-Cap FundRoyce & Associates, LP31,054$2 M0.10%0.50%newJun 30, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC40,511$2 M0.14%<0.01%+2.1%May 31, 2026
🇺🇸 Hartford Small Cap Growth HLS FundHartford Funds Management Company, LLC30,559$2 M0.10%0.31%+15%Jun 30, 2026
🇺🇸 Carillon Chartwell Small Cap FundCarillon Tower Advisers, Inc.28,326$2 M0.09%0.77%+13%Jun 30, 2026
🇺🇸 Franklin Small Cap Enhanced ETFFranklin Advisers, Inc.28,069$2 M0.09%1.5%+139%Jun 30, 2026
🇺🇸 iShares Core S&P Total U.S. Stock Market ETFBlackRock Fund Advisors27,725$2 M0.09%<0.01%+2.0%Jun 30, 2026
🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC26,473$2 M0.09%0.04%+19%Jul 31, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC32,524$2 M0.11%<0.01%+2.7%May 31, 2026
🇺🇸 William Blair Small-Mid Cap Core FundWilliam Blair Investment Management, LLC24,537$2 M0.08%0.63%+172%Jun 30, 2026
🇺🇸 First Trust Small Cap Growth AlphaDEX FundFirst Trust Advisors L.P.25,089$2 M0.08%0.13%newJul 31, 2026
🇺🇸 Alger Small Cap Growth PortfolioFred Alger Management, LLC23,544$2 M0.08%0.98%−34%Jun 30, 2026
🇺🇸 Small Cap Stock TrustJohn Hancock Variable Trust Advisers LLC23,101$2 M0.08%0.53%−1.8%Jun 30, 2026
🇺🇸 American Beacon ARK Transformational Innovation FundAmerican Beacon Advisors, Inc.22,234$2 M0.07%0.95%+4.2%Jun 30, 2026
🇺🇸 Carillon Chartwell Small Cap Growth FundCarillon Tower Advisers, Inc.21,929$2 M0.07%0.77%+32%Jun 30, 2026
🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC21,794$1 M0.07%0.04%+9.7%Jun 30, 2026
🇺🇸 Fidelity Small Cap Growth Index FundFidelity Management & Research Company LLC18,741$1 M0.06%0.08%+30%Jun 30, 2026
🇺🇸 U.S. Core Equity 1 PortfolioDimensional Fund Advisors LP18,197$1 M0.06%<0.01%+164%Jul 31, 2026
🇺🇸 U.S. Small Cap PortfolioDimensional Fund Advisors LP17,892$1 M0.06%<0.01%−76%Jul 31, 2026
🇺🇸 Dimensional U.S. Core Equity 2 ETFDimensional Fund Advisors LP17,852$1 M0.06%<0.01%+46%Jul 31, 2026
🇺🇸 BlackRock Advantage Small Cap Core FundBlackRock Advisors, LLC22,200$1 M0.07%0.02%−22%May 29, 2026
🇺🇸 MassMutual Small Cap Growth Equity FundMML Investment Advisers, LLC15,963$1 M0.05%0.15%−45%Jun 30, 2026
🇺🇸 Nuveen Equity Index FundTeachers Advisors, LLC16,421$1 M0.05%<0.01%no changeJul 31, 2026
🇺🇸 William Blair Growth FundWilliam Blair Investment Management, LLC15,156$1 M0.05%0.46%+18%Jun 30, 2026
🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation14,200$1 M0.05%0.04%+11%Jun 30, 2026
🇺🇸 Vanguard Russell 2000 Growth Index FundThe Vanguard Group, Inc.17,779$1 M0.06%0.05%+1.9%May 31, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC17,559$1 M0.06%<0.01%+4.9%May 31, 2026
🇺🇸 Alger Small Cap Growth FundFred Alger Management, LLC13,974$1 M0.05%0.45%−42%Jul 31, 2026
🇺🇸 The Hartford Small Cap Growth FundHartford Funds Management Company, LLC13,750$1 M0.05%0.32%−10%Jul 31, 2026
🇺🇸 iShares U.S. Small-Cap Equity Factor ETFBlackRock Fund Advisors13,700$1 M0.05%0.02%+133%Jul 31, 2026
🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc.13,176$1 M0.04%<0.01%no changeJul 31, 2026
🇺🇸 NYLIM VP Wellington Small Cap PortfolioNew York Life Investment Management LLC12,177$1 M0.04%0.19%−8.8%Jun 30, 2026
🇺🇸 Fidelity ZERO Total Market Index FundFidelity Management & Research Company LLC12,035$1 M0.04%<0.01%+9.6%Jul 31, 2026
🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC10,450$1 M0.03%0.04%no changeJun 30, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.10,312$1 M0.03%<0.01%−3.9%Jun 30, 2026
🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc.10,124$1 M0.03%0.04%+17%Jun 30, 2026
🇺🇸 Royce Capital Fund - Micro-Cap PortfolioRoyce & Associates, LP10,112$1 M0.03%0.49%—Jun 30, 2026
🇺🇸 Goldman Sachs ActiveBeta U.S. Small Cap Equity ETFGoldman Sachs Asset Management, L.P.12,363$1 M0.04%0.07%+1.3%May 31, 2026
🇺🇸 iShares ESG Aware MSCI USA Small-Cap ETFBlackRock Fund Advisors12,330$1 M0.04%0.03%+56%May 31, 2026
🇺🇸 Schwab U.S. Broad Market ETFCharles Schwab Investment Management, Inc.12,226$1 M0.04%<0.01%no changeMay 31, 2026
🇺🇸 LVIP Franklin Templeton Multi-Factor SMID Cap Equity FundLincoln Financial Investments Corporation9,089$1 M0.03%0.06%+6.7%Jun 30, 2026
🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC9,574$1 M0.03%0.04%+16%Jul 31, 2026
🇺🇸 BlackRock Advantage Small Cap Growth FundBlackRock Funds9,045$1 M0.03%0.07%+27%Jun 30, 2026
🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc.8,978$1 M0.03%<0.01%no changeJun 30, 2026
🇺🇸 Fidelity MSCI Health Care Index ETFFidelity Management & Research Company LLC9,458$1 M0.03%0.02%+2.9%Jul 31, 2026
🇺🇸 Invesco RAFI US 1500 Small-Mid ETFInvesco Capital Management LLC8,774$1 M0.03%0.02%+24%Jul 31, 2026
🇺🇸 One Global ETFThe Future Fund LLC10,837$1 M0.04%0.55%—May 31, 2026
🇺🇸 iShares Morningstar Small-Cap Growth ETFBlackRock Fund Advisors8,113$1 M0.03%0.05%+28%Jul 31, 2026
🇺🇸 Fidelity ZERO Extended Market Index FundFidelity Management & Research Company LLC8,092$1 M0.03%0.02%+7.9%Jul 31, 2026
🇺🇸 Thrivent Aggressive Allocation FundThrivent Asset Management LLC7,917$1 M0.03%0.01%newJul 31, 2026
🇺🇸 Multi-Manager U.S. Small Cap Equity FundGoldman Sachs Asset Management, L.P.7,818$0 M0.03%0.14%—Apr 30, 2026
🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC6,860$0 M0.02%0.02%no changeJun 30, 2026
🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc.6,800$0 M0.02%0.02%+1.5%Jun 30, 2026
🇺🇸 Thrivent Moderately Aggressive Allocation FundThrivent Asset Management LLC7,158$0 M0.02%<0.01%newJul 31, 2026
🇺🇸 JPMorgan BetaBuilders U.S. Small Cap Equity ETFJ.P. Morgan Investment Management Inc.6,851$0 M0.02%0.06%−11%Jul 31, 2026
🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC6,434$0 M0.02%0.04%no changeJun 30, 2026
🇺🇸 PACE Small/Medium Co Growth Equity InvestmentsUBS Asset Management (Americas) LLC6,719$0 M0.02%0.17%+64%Jul 31, 2026
🇺🇸 MML VIP Wellington Small Cap Growth Equity FundMML Investment Advisers, LLC6,241$0 M0.02%0.27%−1.0%Jun 30, 2026
🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC6,196$0 M0.02%0.04%+6.5%Jun 30, 2026
🇸🇪 Handelsbanken Global Småbolag Index CriteriaHandelsbanken Fonder AB6,200$0 M0.02%0.01%+17%Jun 30, 2026
🇺🇸 Small Cap Index FundThe Variable Annuity Life Insurance Company7,767$0 M0.03%0.03%no changeMay 31, 2026
🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC5,777$0 M0.02%0.04%+19%Jun 30, 2026
🇺🇸 Fidelity Nasdaq Composite Index ETFFidelity Management & Research Company LLC7,227$0 M0.02%<0.01%+1.7%May 31, 2026
🇺🇸 JNL/DFA U.S. Small Cap FundJackson National Asset Management, LLC5,173$0 M0.02%0.04%+5.6%Jun 30, 2026
🇺🇸 MFS Blended Research Small Cap Equity FundMASSACHUSETTS FINANCIAL SERVICES COMPANY6,127$0 M0.02%0.10%−75%May 31, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 100 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at GeneDx Holdings Corp.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$106.6 M
34 purchases, 3 insiders
Sold, 12 months
$21.5 M
105 sales, 4 insiders
Net, 12 months
$85.1 M
open market only
Insiders on file
30
since
$82.0 M-$65.4 M$0Nov 2023: bought $176 K (3 trades), sold $1.1 M (1 trades)Nov 23Dec 2023: bought $0 (0 trades), sold $45 K (7 trades)Jan 2024: bought $0 (0 trades), sold $896 (2 trades)Mar 2024: bought $358 K (2 trades), sold $190 K (7 trades)Apr 2024: bought $0 (0 trades), sold $82 K (2 trades)AprMay 2024: bought $5.4 M (5 trades), sold $0 (0 trades)Jun 2024: bought $2.8 M (2 trades), sold $386 K (5 trades)Jul 2024: bought $0 (0 trades), sold $18.6 M (14 trades)Aug 2024: bought $0 (0 trades), sold $11.2 M (7 trades)AugSep 2024: bought $0 (0 trades), sold $653 K (5 trades)Oct 2024: bought $0 (0 trades), sold $65.1 M (3 trades)Nov 2024: bought $0 (0 trades), sold $18.6 M (30 trades)Dec 2024: bought $0 (0 trades), sold $1.5 M (5 trades)DecJan 2025: bought $0 (0 trades), sold $9.9 M (19 trades)Mar 2025: bought $0 (0 trades), sold $7.2 M (11 trades)Apr 2025: bought $0 (0 trades), sold $5.9 M (27 trades)May 2025: bought $8.6 M (5 trades), sold $0 (0 trades)MayJun 2025: bought $0 (0 trades), sold $1.3 M (5 trades)Jul 2025: bought $0 (0 trades), sold $2.1 M (9 trades)Aug 2025: bought $0 (0 trades), sold $65.4 M (8 trades)Sep 2025: bought $0 (0 trades), sold $4.5 M (22 trades)SepOct 2025: bought $0 (0 trades), sold $348 K (3 trades)Nov 2025: bought $0 (0 trades), sold $6.1 M (15 trades)Dec 2025: bought $0 (0 trades), sold $3.0 M (25 trades)Jan 2026: bought $0 (0 trades), sold $185 K (3 trades)Jan 26Feb 2026: bought $0 (0 trades), sold $851 K (12 trades)Mar 2026: bought $13.5 M (10 trades), sold $8.2 M (25 trades)Apr 2026: bought $0 (0 trades), sold $167 K (3 trades)May 2026: bought $82.0 M (22 trades), sold $0 (0 trades)MayJun 2026: bought $11.1 M (2 trades), sold $1.1 M (9 trades)Sep 2026: bought $0 (0 trades), sold $1.8 M (13 trades)
Bought (open market)Sold (open market)Hover a month for the totals
GeneDx Holdings Corp.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Thomas FuchsDirectorOption exercise+1,146——1,146Form 4
filed Katherine StuelandCHIEF EXECUTIVE OFFICER, DirectorOption exercise+18,750——125,977Form 4
filed Kevin FeeleyCHIEF FINANCIAL OFFICEROption exercise+7,197——48,673Form 4
filed Kevin FeeleyCHIEF FINANCIAL OFFICERSell-586$94.26$55 K48,087Form 4
filed Katherine StuelandCHIEF EXECUTIVE OFFICER, DirectorSell-1,648$94.26$155 K124,329Form 4
filed Kevin FeeleyCHIEF FINANCIAL OFFICERSell-52$95.41$5 K48,035Form 4
filed Katherine StuelandCHIEF EXECUTIVE OFFICER, DirectorSell-148$95.41$14 K124,181Form 4
filed Katherine StuelandCHIEF EXECUTIVE OFFICER, DirectorSell-1,525$96.90$148 K122,656Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: GeneDx Holdings Corp.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
6.6 M
22.4% of shares · 7.27 days to cover
Shares sold short, last 24 reportsAll stocks →

Stock splits: 1-for-33.33 reverse split

Fails to deliver

  • : 459 shares at $71.02
  • : 1,833 shares at $64.69
  • : 120 shares at $61.26
  • : 7,286 shares at $66.29
  • : 8 shares at $76.27

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

GeneDx Holdings Corp. scorecard#

Passes 9 of the 18 checks that could be worked out: strongest in growth (4 of 5), weakest in valuation (0 of 3). Fiscal year 2025; market cap of Oct 30, 2026.

  • Valuation0 of 3
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • –Price to book below its peers' medianToo few peers with a current market cap for a median.
    • –Price to sales below its peers' medianToo few peers with a current market cap for a median.
    • ✗Free cash flow yield above 5%0.7%Free cash flow is 0.7% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth4 of 5
    • ✓Revenue grew in the newest year40.0%Revenue up 40.0% in fiscal 2025.
    • ✓Revenue up more than 5% a year over three years22.1%22.1% a year over the three years to fiscal 2025.
    • –Faster growth over three years than its peers' medianToo few peers for a median.
    • ✗Earnings per share grew in the newest year-0.73 vs -1.94Diluted EPS -0.73 in fiscal 2025 against -1.94 the year before (report's currency).
    • ✓Net income higher than five years earlier-$21 M-$21 M in fiscal 2025 against -$241 M in 2020.
    • ✓Revenue rose in at least four of the last five years4 of 5Revenue rose in 4 of the five years to fiscal 2025.
  • Profitability1 of 4
    • ✗Profitable in the newest year-$21 MNet income -$21 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • –Operating margin above its peers' medianToo few peers for a median.
    • ✗Return on equity above 15%-7.6%-7.6% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • ✓Operating margin wider than three years earlier-3.1%-3.1% in fiscal 2025 against -284.5% in 2022.
  • Financial health4 of 5
    • ✓Short-term assets cover short-term liabilities2.5×Current ratio 2.46 at the end of fiscal 2025.
    • ✓Debt below equity0.2×Debt to equity 0.18 at the end of fiscal 2025.
    • ✓Net debt below three years of EBITDANet cashMore cash than debt: net cash of $50 M at the end of fiscal 2025.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years1 of 3Positive in 1 of the three years to fiscal 2025.
    • ✓Altman Z-score outside the distress zone3.35Z-score 3.35 (safe zone) for fiscal 2025.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year6.5%Diluted shares up 6.5% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2025#

Worked out from GeneDx Holdings Corp.'s statements.

GeneDx Holdings Corp.: main financial ratios in 2025
Ratio2025
Operating margin-3.1%
Net margin-4.9%
Return on equity-7.6%
Revenue growth, 3 years a year22.1%
Revenue growth40.0%
Debt to equity0.18×

6of 9on the Piotroski tests of financial strength

  • Net loss of $21 million, the 7th loss-making year in a row.
  • The share count rose 6.5% in the year.
  • Receivables grew 98% while revenue grew 40%: customers are paying later, or sales were booked ahead of cash.
  • More cash than debt: net cash of $50 million.

GeneDx Holdings Corp.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

GeneDx Holdings Corp.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019
Income statement
Revenue428305203235212179196
Cost of revenue129111113261229175113
Gross profit29819490−27−174.083
Research and development724658861057335
Selling and marketing886761122r1136339
General and administrative151105r139r216r20610129
Operating income−13−23−181−668−446−242−30
Interest and finance income———2.50.10.51.0
Interest expense and finance costs———3.22.82.50.8
Net interest income——1.1−0.7———
Other non-operating income (expense)−8.1−293.9702010.70.7
Income before tax−21−53−177−598−245−241−30
Income tax−0.1−0.3−0.9−49000
Net income attributable to shareholders−21−52−176−549−245−241−30
Earnings per share, basic-0.73-1.94-7.23-53.63r-2.27-47,036.00-264,056.00
Earnings per share, diluted-0.73-1.94-7.23-53.63r-2.27-47,036.00-264,056.00
Shares, weighted average (basic)29272410r1080.00.0
Shares, weighted average (diluted)29272410r1080.00.0
Balance sheet
Cash and cash equivalents10585100124401108r115
Short-term investments6656300———
Receivables7438r—432732—
Inventory14118.8143325—
Other current assets1.51.1r2.0r6.43.84.1—
Current assets268198182213484174r—
Property, plant and equipment463332526363—
Right-of-use (leased) assets232627330——
Goodwill140——00—
Other intangible assets1681591731870——
Total assets524419419491554252r—
Accounts payable2.58.010464527r—
Debt due within a year4.51.20.54.801.8—
Current liabilities109555914410173r—
Long-term debt4852536.31119—
Lease liabilities (non-current)39434444———
Total liabilities216174191237166247r—
Retained earnings−1,373−1,352−1,300−1,124−575−330r—
Shareholders' equity308245228254388−330r−89
Total liabilities and equity524419419491554252r—
Shares outstanding29282612243——
Cash-flow statement
Depreciation and amortization9.67.92050r22126.4
Share-based compensation329.1−0.3422191205.5
Cash from operating activities33−28−180−319−190−93−19
Capital expenditure−19−5.5−5.3−7.2−9.4−24−12
Acquisitions, net of cash acquired—0−12−12700—
Cash from investing activities−62−30−44−141−21−32−15
Debt issued004900160
Shares issued———19835000
Cash from financing activities4844186197494129148
Change in cash20−14−38−2632834.0114
Report10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

What GeneDx Holdings Corp. sells: revenue by product line, fiscal 2025#

As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.

Products and services

  • Diagnostic Test$417 M97%
  • Patients with third-party insurance$345 M81%
  • Institutional customers$70 M16%
  • Other revenue$11 M2.5%
  • Self-pay patients$1 M0.3%

Business segments

  • GeneDx$423 M99%
  • Other$4 M1.0%

Source: SEC annual report (XBRL data) · as of Dec 31, 2025

Where GeneDx Holdings Corp. operates: 1 country#

Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue.

Present: offices, subsidiaries, branches or revenue (1 country)Nothing on fileDots mark countries too small to see. Hover, tap or tab to a country for its figures.

Only the headquarters country is on file for GeneDx Holdings Corp.: no subsidiaries, branches, offices or country revenue elsewhere in the GLEIF register, its SEC filings or Wikidata.

GeneDx Holdings Corp.: countries of operation
CountryPresenceRevenue there
🇺🇸 USAHeadquarters1 office—

Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file; map outlines from Natural Earth. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided

Executive pay at GeneDx Holdings Corp.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$13.5 M
Katherine Stueland
Other top executives, average
$4.1 M
the CEO earned 3.3× this
$100 invested is now
$1494
peer group: $139
GeneDx Holdings Corp.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025Katherine Stueland$13.5 M$43.4 M$4.1 M$1494 (peers $139)
2024Katherine Stueland$4.4 M$51.5 M$896 K$883 (peers $104)
2023Katherine Stueland$3.5 M$546 K$1.2 M$32 (peers $105)

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025

Events at GeneDx Holdings Corp.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.

Directors and officers 3 · Material agreement 3 · Agreement ended 1 · New debt 1 · Unregistered share sale 1 · Shareholder vote 3 · Results announced 15

GeneDx Holdings Corp.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Results announced8-K
Shareholder vote8-K
Directors and officers8-K
Results announced8-K
Material agreementAgreement endedNew debt8-K
Results announced8-K
Results announced8-K
Results announced8-K
Directors and officers8-K
Results announced8-K
Shareholder vote8-K
Results announced8-K
Material agreementUnregistered share sale8-K
Results announced8-K
Results announced8-K
Directors and officers8-K
Results announced8-K
Results announced8-K
Shareholder vote8-K
Results announced8-K
Material agreement8-K
Results announced8-K
Results announced8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 9, 2026

Acquisitions and funding#

2 acquisitions, $49 M paid where reported

Businesses it acquired

Acquisitions by GeneDx Holdings Corp.
AcquiredAcquisition dateCompletionPriceStakeSource
Fabric Genomics, Inc2025—$37 M—Annual report
GeneDx2023—$12 M—Annual report

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

Lobbying by GeneDx Holdings Corp.#

$240 K spent on lobbying the US Congress and federal agencies in 2025, most often on health issues and medicare/medicaid.

Lobbying, 2025
$240 K
#902 among companies on value.today
Own lobbyists
No
only outside firms
Firms hired
2
in 2025
2026 so far
$270 K
  • Health Issues3 reports
  • Medicare/Medicaid3 reports

Lobbying firms hired in 2025

Red+Blue Strategies( formerly known as Nathanson+Hauck) $160 K · Red+Blue Strategies $80 K

GeneDx Holdings Corp.: lobbying spending by year
YearSpendingOwn lobbyistsReports
2026 (so far)$270 K—4
2025$240 K—3
2022$53 K—2
2021$0—1

Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “GeneDx, LLC”, “GeneDx, Inc.” and “GeneDx”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero

H-1B hiring at GeneDx Holdings Corp.#

4 labor condition applications certified in fiscal 2026 for 4 positions, at a median wage of $163 K a year.

Certified, FY2026
4
#1,250 among companies on value.today
Worker positions
4
Median wage offered
$163 K
a year, full-time
Applications filed
4
GeneDx Holdings Corp.: most frequent H-1B job titles in fiscal 2026
Job titlePositionsMedian wage offered
Backend Software EngineerSoftware Developers2$125 K
Director, CX Engineering-Order ManagementComputer and Information Systems Managers1$203 K
Senior Director, Strategic ForecastingBusiness Intelligence Analysts1$200 K

Where: Binghamton, NY 2 · Lisle, IL 1 · New York, NY 1

GeneDx Holdings Corp.: labor condition applications by fiscal year
Fiscal yearCertifiedPositionsMedian wageFiled
FY202644$163 K4
FY202411$200 K1

Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as GeneDx, LLC

Layoffs at GeneDx Holdings Corp.#

From US state WARN notices and SEC 8-K restructuring filings, newest first.

People, last 12 months
0
0 notices and filings
People, all years
500
2022–2022
Latest
500 people
2022-11-11
GeneDx Holdings Corp.: people laid off by year and month
YearJanFebMarAprMayJunJulAugSepOctNovDecTotal
2022··········500·500
GeneDx Holdings Corp.: latest layoffs
AnnouncedPeopleKindWhereSource
500 people (32.5% of workforce)Restructuring planSEC 8-K“As a result of this announcement, the Company expects to eliminate approximately 500 positions, representing approximately 32.5% of its workforce, and to cease operations at its St…”Filing

Source: State WARN notices and SEC 8-K item 2.05

Discuss GeneDx Holdings Corp.#

2 automatic updates and 0 member comments. Sign in to comment and react.

  • Results announced on 9 November 2026automatic update · Nov 9, 2026

    GeneDx Holdings Corp. announced results on 9 November 2026 (SEC Form 8-K, item 2.02). For the quarter ended 30 September 2026: revenue of $123 million (up 5% from a year earlier) and a net loss of $12 million.

  • Mutual funds: 180 funds hold $458 millionautomatic update · Jul 31, 2026

    180 mutual funds in 2 countries hold shares of GeneDx Holdings Corp. worth $458 million, about 23.3% of the company (funds' newest reports, up to 31 July 2026). Since their previous reports 117 funds added shares and 107 sold; on balance they sold $173 million. Share splits are not counted as trading.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 30, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at GeneDx Holdings Corp.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show GeneDx Holdings Corp.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about GeneDx Holdings Corp.? Suggest a correction